The power in numbers: Gut microbiota in Parkinson's disease

Movement Disorders

Volumn 30, Issue 3, 2015, Pages 296-298

  Vizcarra, Joaquin A ^a   Wilson Perez, Hilary E ^b,c   Espay, Alberto J ^b,c  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Gardner Family Center for Parkinson's Disease and Movement Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; CYCLIC AMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN AGGREGATE; SHORT CHAIN FATTY ACID;

ANTIBODY PRODUCTION; ASTHMA; BACTERIAL GENOME; CANCER SCREENING; CARDIOVASCULAR DISEASE; CLOSTRIDIUM PERFRINGENS; COLORECTAL ADENOMA; COLORECTAL CANCER; CYTOKINE PRODUCTION; EDITORIAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTERNAL VALIDITY; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MICROBIOME; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; OBESITY; PARKINSON DISEASE; PREVOTELLACEAE; PRIORITY JOURNAL; PROTEIN DEGRADATION; FEMALE; MALE; MICROBIOLOGY;

FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; PARKINSON DISEASE;

EID: 84924625560     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26116     Document Type: Editorial

References (32)

1. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 1998;95:6578-6583.
2. Peterson J, Garges S, Giovanni M, et al. The NIH Human Microbiome Project. Genome Res 2009;19:2317-2323.
3. Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res 2014; doi: 10.1158/1940-6207.
4. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014;40:843-854.
5. Rooks MG, Veiga P, Wardwell-Scott LH, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J 2014;8:1403-1417.
6. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 2014;146:1449-1458.
7. Foxx-Orenstein AE, Chey WD. Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. Am J Gastroenterol Suppl. American College of Gastroenterology 2012;1:41-46.
8. Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 2014;9:399-410.
9. Rumah KR, Linden J, Fischetti VA, Vartanian T. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One 2013;8:e76359.
10. Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009;183:6041-6050.
11. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2014; [Epub ahead of print].
12. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011;473:174-180.
13. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-1638.
14. Lin A, Bik EM, Costello EK, et al. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS One 2013;8:e53838.
15. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012;486:222-227.
16. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
17. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
18. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012;27:716-719.
19. Hilton D, Stephens M, Kirk L, et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol 2014;127:235-241.
20. Olanow CW, Wakeman DR, Kordower JH. Peripheral alpha-synuclein and Parkinson's disease. Mov Disord 2014;29:963-966.
21. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
22. Luk KC, Lee VM-Y. Modeling Lewy pathology propagation in Parkinson's disease. Parkinsonism Relat Disord 2014;20(Suppl 1):S85-S87.
23. Abt MC, Artis D. The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol 2009;25:496-502.
24. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011;6:e28032.
25. Niehaus I, Lange JH. Endotoxin: is it an environmental factor in the cause of Parkinson's disease? Occup Environ Med 2003;60:378.
26. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014;156:84-96.
27. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis 2013;50:42-48.
28. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 2010;5:e12728.
29. Uversky VN. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 2003;21:211-234.
30. Bousset L, Pieri L, Ruiz-Arlandis G, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun 2013;4:2575.
31. Allen-Vercoe E, Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC? Immunol Lett 2014 Jun 24 [Epub ahead of print].
32. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014;29:454-462.